The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Open accessAbstract
Chimeric antigen receptor (CAR) T-cells directed against the B-cell marker CD19 are currently changing the landscape for treatment of patients with refractory and/or relapsed B-cell malignancies. Due to the nature of CAR T-cells as living drugs, they display a unique toxicity profile. As CAR T-cell therapy is extending towards other diseases and being more broadly employed in hematology and oncology, optimal management strategies of side-effects associated with CAR T-cell therapy are of high relevance. Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias constitute challenges in the treatment of patients with CAR T-cells. This review summarizes the current understanding of CAR T-cell toxicity and its management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Henter, J., Horne, A., Aricó, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K., Webb, D., Winiarski, J., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21039 · Cited by 5,386
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156
Gardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
Ott, M. G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kühlcke, K., Schilz, A., Kunkel, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1393 · Cited by 1,051
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886
Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M. S., Brüggemann, M., Horst, H.-A., et al. (2018) · Blood · doi:10.1182/blood-2017-08-798322 · Cited by 858
Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02104 · Cited by 801
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Brudno, J. N., Maric, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler-Stevenson, M., Salem, D., Yuan, C., Pavletic, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 781
Ravelli, A., Minoia, F., Davì, S., Horne, A., Bovis, F., Pistorio, A., Aricò, M., Avcin, T., Behrens, E. M., De Benedetti, F., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39332 · Cited by 773
Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Turtle, C. J., Hay, K. A., Hanafi, L.-A., Li, D., Cherian, S., Chen, X., Wood, B., Lozanski, A., Byrd, J. C., Heimfeld, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.8519 · Cited by 662
Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0201-9 · Cited by 659
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
Interleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Sterner, R. M., Sakemura, R., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881722 · Cited by 621
Brudno, J. N., Somerville, R. P. T., Shi, V., Rose, J. J., Halverson, D. C., Fowler, D. H., Gea-Banacloche, J. C., Pavletic, S. Z., Hickstein, D. D., Lu, T. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.5929 · Cited by 605
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 590
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Maus, M. V., Haas, A. R., Beatty, G. L., Albelda, S. M., Levine, B. L., Liu, X., Zhao, Y., Kalos, M., & June, C. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0006 · Cited by 586
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Hill, J. A., Li, D., Hay, K. A., Green, M. L., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., Boeckh, M., & Turtle, C. J. (2018) · Blood · doi:10.1182/blood-2017-07-793760 · Cited by 576
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3024 · Cited by 569
Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone Marrow
Halliley, J. L., Tipton, C. M., Liesveld, J., Rosenberg, A. F., Darce, J., Gregoretti, I. V., Popova, L., Kaminiski, D., Fucile, C. F., Albizua, I., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.016 · Cited by 545
Traube, C., Silver, G., Kearney, J., Patel, A., Atkinson, T. M., Yoon, M. J., Halpert, S., Augenstein, J., Sickles, L. E., Li, C., et al. (2014) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182a66b76 · Cited by 533
Zhao, W.-H., Liu, J., Wang, B.-Y., Chen, Y.-X., Cao, X.-M., Yang, Y., Zhang, Y.-L., Wang, F.-X., Zhang, P.-Y., Lei, B., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0681-6 · Cited by 518
Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 443
Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03279 · Cited by 421
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
Porter, D., Frey, N., Wood, P. A., Weng, Y., & Grupp, S. A. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0571-y · Cited by 401
Early and late hematologic toxicity following CD19 CAR-T cells
Fried, S., Avigdor, A., Bielorai, B., Meir, A., Besser, M. J., Schachter, J., Shimoni, A., Nagler, A., Toren, A., & Jacoby, E. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0487-3 · Cited by 401
Glucocorticoids in T cell apoptosis and function
Herold, M. J., McPherson, K. G., & Reichardt, H. M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5390-y · Cited by 397
Ramos, C. A., Ballard, B., Zhang, H., Dakhova, O., Gee, A. P., Mei, Z., Bilgi, M., Wu, M.-F., Liu, H., Grilley, B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94306 · Cited by 375
Self-citationYakoub-Agha, I., Chabannon, C., Bader, P., Basak, G. W., Bonig, H., Ciceri, F., Corbacioglu, S., Duarte, R. F., Einsele, H., Hudecek, M., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.229781 · Cited by 365
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Cordeiro, A., Bezerra, E. D., Hirayama, A. V., Hill, J. A., Wu, Q. V., Voutsinas, J., Sorror, M. L., Turtle, C. J., Maloney, D. G., & Bar, M. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2019.08.003 · Cited by 364
G-CSF and GM-CSF in Neutropenia
Mehta, H. M., Malandra, M., & Corey, S. J. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500861 · Cited by 363
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
Alvi, R. M., Frigault, M. J., Fradley, M. G., Jain, M. D., Mahmood, S. S., Awadalla, M., Lee, D. H., Zlotoff, D. A., Zhang, L., Drobni, Z. D., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.038 · Cited by 356
Karschnia, P., Jordan, J. T., Forst, D. A., Arrillaga-Romany, I. C., Batchelor, T. T., Baehring, J. M., Clement, N. F., Gonzalez Castro, L. N., Herlopian, A., Maus, M. V., et al. (2019) · Blood · doi:10.1182/blood-2018-12-893396 · Cited by 351
Santomasso, B., Bachier, C., Westin, J., Rezvani, K., & Shpall, E. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238691 · Cited by 330
Managing the toxicities of CAR T‐cell therapy
Neelapu, S. S. (2019) · Hematological Oncology · doi:10.1002/hon.2595 · Cited by 328
Brudno, J. N., Lam, N., Vanasse, D., Shen, Y.-W., Rose, J. J., Rossi, J., Xue, A., Bot, A., Scholler, N., Mikkilineni, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0737-3 · Cited by 311
Fluid Resuscitation in Sepsis: A Systematic Review and Network Meta-analysis
Rochwerg, B., Alhazzani, W., Sindi, A., Heels-Ansdell, D., Thabane, L., Fox-Robichaud, A., Mbuagbaw, L., Szczeklik, W., Alshamsi, F., Altayyar, S., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0178 · Cited by 309
Gardner, R. A., Ceppi, F., Rivers, J., Annesley, C., Summers, C., Taraseviciute, A., Gust, J., Leger, K. J., Tarlock, K., Cooper, T. M., et al. (2019) · Blood · doi:10.1182/blood.2019001463 · Cited by 286
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Yang, J. C., Sherry, R. M., Feldman, S. A., McIntyre, L., Bot, A., Rossi, J., Lam, N., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.004 · Cited by 284
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
Staedtke, V., Bai, R.-Y., Kim, K., Darvas, M., Davila, M. L., Riggins, G. J., Rothman, P. B., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2018) · Nature · doi:10.1038/s41586-018-0774-y · Cited by 277
Bhoj, V. G., Arhontoulis, D., Wertheim, G., Capobianchi, J., Callahan, C. A., Ellebrecht, C. T., Obstfeld, A. E., Lacey, S. F., Melenhorst, J. J., Nazimuddin, F., et al. (2016) · Blood · doi:10.1182/blood-2016-01-694356 · Cited by 276
Park, J. H., Romero, F. A., Taur, Y., Sadelain, M., Brentjens, R. J., Hohl, T. M., & Seo, S. K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy152 · Cited by 276
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Frey, N. V., Shaw, P. A., Hexner, E. O., Pequignot, E., Gill, S., Luger, S. M., Mangan, J. K., Loren, A. W., Perl, A. E., Maude, S. L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01892 · Cited by 271
Logue, J. M., Zucchetti, E., Bachmeier, C. A., Krivenko, G. S., Larson, V., Ninh, D., Grillo, G., Cao, B., Kim, J., Chavez, J. C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.238634 · Cited by 271
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Gust, J., Taraseviciute, A., & Turtle, C. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0582-9 · Cited by 264
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1368 · Cited by 256
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Mahadeo, K. M., Khazal, S. J., Abdel-Azim, H., Fitzgerald, J. C., Taraseviciute, A., Bollard, C. M., Tewari, P., Duncan, C., Traube, C., McCall, D., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0075-2 · Cited by 238
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Mueller, K. T., Waldron, E., Grupp, S. A., Levine, J. E., Laetsch, T. W., Pulsipher, M. A., Boyer, M. W., August, K. J., Hamilton, J., Awasthi, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0758 · Cited by 228
Zhang, X., Lu, X.-A., Yang, J., Zhang, G., Li, J., Song, L., Su, Y., Shi, Y., Zhang, M., He, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001466 · Cited by 214
Schwarzwaelder, K., Howe, S. J., Schmidt, M., Brugman, M. H., Deichmann, A., Glimm, H., Schmidt, S., Prinz, C., Wissler, M., King, D. J. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31661 · Cited by 203
Chen, F., Teachey, D. T., Pequignot, E., Frey, N., Porter, D., Maude, S. L., Grupp, S. A., June, C. H., Melenhorst, J. J., & Lacey, S. F. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.03.005 · Cited by 195
Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapy
Gust, J., Finney, O. C., Li, D., Brakke, H. M., Hicks, R. M., Futrell, R. B., Gamble, D. N., Rawlings‐Rhea, S. D., Khalatbari, H. K., Ishak, G. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25502 · Cited by 194
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions
Hunter, B. D., & Jacobson, C. A. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz017 · Cited by 193
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Lekakis, L. J., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1547.1547 · Cited by 184
Frey, N. V., Gill, S., Hexner, E. O., Schuster, S., Nasta, S., Loren, A., Svoboda, J., Stadtmauer, E., Landsburg, D. J., Mato, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03237 · Cited by 179
Liu, S., Deng, B., Yin, Z., Pan, J., Lin, Y., Ling, Z., Wu, T., Chen, D., Chang, A. H., Gao, Z., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0280-y · Cited by 161
Sachdeva, M., Duchateau, P., Depil, S., Poirot, L., & Valton, J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.007558 · Cited by 159
Riegler, L. L., Jones, G. P., & Lee, D. W. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s150524 · Cited by 158
Pennisi, M., Jain, T., Santomasso, B. D., Mead, E., Wudhikarn, K., Silverberg, M. L., Batlevi, Y., Shouval, R., Devlin, S. M., Batlevi, C., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000952 · Cited by 158
Howard, S. C., Trifilio, S. M., Gregory, T. K., Baxter, N., & McBride, A. (2016) · Annals of Hematology · doi:10.1007/s00277-015-2585-7 · Cited by 152
Wudhikarn, K., Pennisi, M., García‐Recio, M., Flynn, J. R., Afuye, A. O., Silverberg, M. L., Maloy, M., Devlin, S. M., Batlevi, C. L., Shah, G. L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001972 · Cited by 152
Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function
Singh, N., Hofmann, T. J., Gershenson, Z., Levine, B. L., Grupp, S. A., Teachey, D. T., & Barrett, D. M. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.04.001 · Cited by 151
Awasthi, R., Pacaud, L. B., Waldron, E. K., Tam, C. S. L., Jaeger, U., Borchmann, P., Jaglowski, S. M., Foley, S. R., van Besien, K., Wagner‐Johnston, N. D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000525 · Cited by 151
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W. G., Locke, F. L., Lin, Y., Jain, N., Daver, N. G., Gulbis, A. M., Adkins, S., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.20 · Cited by 148
Tumor Lysis Syndrome in Patients with Hematological Malignancies
Belay, Y., Yirdaw, K., & Enawgaw, B. (2017) · Journal of Oncology · doi:10.1155/2017/9684909 · Cited by 146
In the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy
Borrega, J. G., Gödel, P., Rueger, M. A., Onur, O. A., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000191 · Cited by 144
Burstein, D. S., Maude, S. L., Grupp, S. A., Griffis, H. M., Rossano, J., & Lin, K. Y. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.05.014 · Cited by 137
Obstfeld, A. E., Frey, N. V., Mansfield, K. G., Lacey, S. F., June, C. H., Porter, D. L., Melenhorst, J. J., & Wasik, M. A. (2017) · Blood · doi:10.1182/blood-2017-08-802413 · Cited by 134
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Titov, A., Petukhov, A., Staliarova, A., Motorin, D., Bulatov, E., Shuvalov, O. Y., Soond, S. M., Piacentini, M., Melino, G., Zaritskey, A. Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0918-x · Cited by 134
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema
Torre, M., Solomon, I. H., Sutherland, C. L., Nikiforow, S., DeAngelo, D. J., Stone, R. M., Vaitkevicius, H., Galinsky, I. A., Padera, R. F., Trede, N. S., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly064 · Cited by 132
Gupta, S., Seethapathy, H. S., Strohbehn, I. A., Frigault, M. J., O’Donnell, E., Jacobson, C. A., Motwani, S. S., Parikh, S. M., Curhan, G. C., Reynolds, K. L., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.10.011 · Cited by 129
van der Stegen, S. J. C., Davies, D. M., Wilkie, S., Foster, J., Sosabowski, J. K., Burnet, J., Whilding, L. M., Petrovic, R. M., Ghaem-Maghami, S., Mather, S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301523 · Cited by 126
Nellan, A., McCully, C. L., Garcia, R. C., Jayaprakash, N., Widemann, B. C., Lee, D. W., & Warren, K. E. (2018) · Blood · doi:10.1182/blood-2018-05-846428 · Cited by 123
Neurotoxicity after CTL019 in a pediatric and young adult cohort
Gofshteyn, J. S., Shaw, P. A., Teachey, D. T., Grupp, S. A., Maude, S. L., Banwell, B., Chen, F., Lacey, S. F., Melenhorst, J. J., Edmondson, M. J., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25315 · Cited by 123
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.19 · Cited by 121
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M. L., Arnason, J. E., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C. B., et al. (2019) · Blood · doi:10.1182/blood-2019-127508 · Cited by 116
Uhlig, C., Silva, P. L., Deckert, S., Schmitt, J. M., & de Abreu, M. G. (2014) · Critical Care · doi:10.1186/cc13187 · Cited by 115
Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.068 · Cited by 110
Tocilizumab in the treatment of rheumatoid arthritis and beyond
Shetty, A., Hanson, R. L., Korsten, P., Shawagfeh, M., Arami, S., Volkov, S., Vila, O. M., Swedler, W., Shunaigat, A. N., Smadi, S., et al. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s41437 · Cited by 108
Acharya, U. H., Dhawale, T. M., Yun, S., Jacobson, C. A., Chávez, J. C., Ramos, J., Appelbaum, J., & Maloney, D. G. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1585238 · Cited by 107
Bachanová, V., Sarhan, D., DeFor, T. E., Cooley, S., Panoskaltsis‐Mortari, A., Blazar, B. R., Curtsinger, J., Burns, L. J., Weisdorf, D. J., & Miller, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2100-1 · Cited by 105
Hypogammaglobulinemia due to CAR T‐cell therapy
Doan, A., & Pulsipher, M. A. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26914 · Cited by 99
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
Cornetta, K., Duffy, L., Turtle, C. J., Jensen, M., Forman, S., Binder-Scholl, G., Fry, T., Chew, A., Maloney, D. G., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.008 · Cited by 98
Pasquini, M. C., Locke, F. L., Herrera, A. F., Siddiqi, T., Ghobadi, A., Komanduri, K. V., Hu, Z., Dong, H., Hematti, P., Nikiforow, S., et al. (2019) · Blood · doi:10.1182/blood-2019-124750 · Cited by 96
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience
Cruz, C. C., Hanley, P. J., Liu, H., Torrano, V., Lin, Y., Arce, J. A., Gottschalk, S. M., Savoldo, B., Dotti, G., Louis, C. U., et al. (2010) · Cytotherapy · doi:10.3109/14653241003709686 · Cited by 89
Schuster, S. J., Maziarz, R. T., Rusch, E. S., Li, J., Signorovitch, J., Romanov, V. V., Locke, F. L., & Maloney, D. G. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001304 · Cited by 81
Mahmoudjafari, Z., Hawks, K. G., Hsieh, A. A., Plesca, D. C., Gatwood, K. S., & Culos, K. A. A. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.09.024 · Cited by 80
Hill, J. A., Krantz, E. M., Hay, K. A., Dasgupta, S., Stevens‐Ayers, T., Ignacio, R. B., Bar, M., Maalouf, J., Cherian, S., Chen, X., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000717 · Cited by 78
Albumin infusion improves endothelial function in septic shock patients: a pilot study
Hariri, G., Joffre, J., Deryckère, S., Bigé, N., Dumas, G., Baudel, J.-L., Maury, É., Guidet, B., & Ait‐Oufella, H. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5075-2 · Cited by 76
Astrakhan, A., Sather, B. D., Ryu, B. Y., Khim, S., Singh, S., Humblet‐Baron, S., Ochs, H. D., Miao, C. H., & Rawlings, D. J. (2012) · Blood · doi:10.1182/blood-2011-03-340711 · Cited by 74
Jain, M. D., & Davila, M. L. (2017) · Stem Cells · doi:10.1002/stem.2715 · Cited by 67
Jin, Z., Xiang, R., Qing, K., Li, X., Zhang, Y., Wang, L., Zhu, H., Mao, Y., Xu, Z., & Li, J. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3368-8 · Cited by 60
Self-citationGutiérrez, C., Brown, A. R., Herr, M. M., Kadri, S. S., Hill, B. T., Rajendram, P., Duggal, A., Turtle, C. J., Patel, K. B., Lin, Y., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.04.008 · Cited by 57
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
Jain, T., & Litzow, M. R. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620719899897 · Cited by 56
Hashmi, H., Bachmeier, C. A., Chávez, J. C., Song, J., Hussaini, M., Krivenko, G. S., Nishihori, T., Kotani, H., Davila, M. L., Locke, F. L., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16155 · Cited by 55
Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy
Cao, W., Wei, J., Wang, N., Xu, H., Xiao, M., Huang, L., Cao, Y., Li, C., Xiao, Y., Gu, C., et al. (2020) · Blood · doi:10.1182/blood.2020004907 · Cited by 49
Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells
Frey, N. V., Levine, B. L., Lacey, S. F., Grupp, S. A., Maude, S. L., Schuster, S. J., Shaw, P. A., Hwang, W., Wasik, M. A., Obstfeld, A. E., et al. (2014) · Blood · doi:10.1182/blood.v124.21.2296.2296 · Cited by 47
Arnold, D. E., Maude, S. L., Callahan, C. A., DiNofia, A. M., Grupp, S. A., & Heimall, J. R. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28092 · Cited by 46
Cao, J., Wang, H., Gao, W., You, J., Wu, L.-H., & Wang, Z.-X. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.01.015 · Cited by 46
Grupp, S. A., Hu, Z., Zhang, Y., Keating, A. K., Pulsipher, M. A., Phillips, C. L., Margossian, S. P., Rosenthal, J., Salzberg, D. B., Schiff, D. E., et al. (2019) · Blood · doi:10.1182/blood-2019-129279 · Cited by 39
Schubert, M., Dietrich, S., Stilgenbauer, S., Schmitt, A., Pavel, P., Kunz, A. B., Bondong, A., Wegner, M., Stadtherr, P., Jung, S., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.025 · Cited by 37
Self-citationManaging Tumor Lysis Syndrome in the Era of Novel Cancer Therapies
McBride, A., Trifilio, S. M., Baxter, N., Gregory, T. K., & Howard, S. C. (2017) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2017.8.7.4 · Cited by 35
Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans
Guenther, S. P. W., Bauer, S., Hagge, M., Knake, S., Olmes, D. G., Tackenberg, B., Rosenow, F., & Hamer, H. M. (2014) · Seizure · doi:10.1016/j.seizure.2014.04.011 · Cited by 31
Management of T-Cell Engaging Immunotherapy Complications
Varadarajan, I., & Lee, D. W. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000377 · Cited by 23
Lin, Q., Liu, X., Han, L., Liu, L., Fang, B., Gao, Q., & Song, Y. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0674-2 · Cited by 23
Lee, D. W., Wayne, A. S., Huynh, V., Handgretinger, R., Pieters, R., Michele, G., Baruchel, A., Feuchtinger, T. F., Bertrand, Y., Hemiston, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx373.014 · Cited by 9
Brudno, J. N., Hartman, S. D., Lam, N., Stroncek, D. F., Rossi, J. M., Shen, Y.-W., Xue, A. X., Bot, A. I., Kanakry, J. A., Pavletic, S. Z., et al. (2018) · Blood · doi:10.1182/blood-2018-99-113731 · Cited by 8
Cappell, K. M., Sherry, R. M., Yang, J. C.-H., Goff, S. L., Vanasse, D., McIntyre, L. S., Rosenberg, S. A., & Kochenderfer, J. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3012 · Cited by 4
Cited by
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou-el-Enein, M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 554
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 310
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
Metadata
- Authors
- Schubert, M.-L., Schmitt, M., Wang, L., Ramos, C. A., Jordan, K., Müller-Tidow, C., & Dreger, P.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 32
- Issue
- 1
- Pages
- 34-48
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3093752130
- Cited by
- 491
- References
- 149
- FWCI
- 18.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.